AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Rigel Pharmaceuticals, Inc.
Video analysis: RIGL
All videosNo video analysis for this stock yet. Request one from our team.
News: RIGL
Rigel to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: Citi's 2026 Biopharma Back to School Conference in New York, NY Rigel will participate in one-on-one meetings on Wednesday, September 9.
18,800 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Canada Pension Plan Investment Board
Canada Pension Plan Investment Board acquired a new position in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 18,800 shares of the biotechnology company's stock, valued at approximately $735,000. Canada Pension Plan Investment
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL
Connor Clark and Lunn Investment Management Ltd. bought a new stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 49,096 shares of the biotechnology company's stock, valued at approximately $1,921,000. Connor Clark
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC), as detected by a U.S. Food and Drug Administration (FDA)-authorized test, with disease progression following at least one line of endocrine therapy.
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and Rezlidhia trials provide additional growth catalysts.
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product sales; net product sales guidance unchanged. VEPPANU is strategically sound but adds only incremental value after upfront payments, milestones, and high royalties.
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript
Rigel Pharmaceuticals Q2 Earnings Call Highlights
Rigel Pharmaceuticals NASDAQ: RIGL reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million, while outlining plans to launch newly licensed breast cancer therapy VEPPANU in mid-August.
